SCHEMBL6339792

SCHEMBL6339792

COC(=O)c1ccccc1NC(=O)Cc1ccc(Oc2ccc3cc(O[C@H]4CC[C@@H](N(Cc5ccccc5)Cc5ccccc5)CC4)ccc3c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.42
POLB P06746 1/20 0.42
ALDH1A1 P00352 6/20 0.41
TACR1 P25103 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41
MAPK10 P53779 3/20 0.40
KMT2A Q03164 3/20 0.40
TSHR P16473 2/20 0.40
HSD17B10 Q99714 2/20 0.40
MEN1 O00255 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPK8 P45983 2/20 0.39
MAPK9 P45984 1/20 0.39
PDE5A O76074 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PKM P14618 1/20 0.39
GAA P10253 1/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6339790 1.00 KDM4E (0.42) KDM4EPOLBALDH1A1TACR1HCAR2
SCHEMBL6346430 0.98 TACR1 (0.42) KDM4EPOLBALDH1A1TACR1HCAR2
SCHEMBL6346432 0.98 TACR1 (0.42) KDM4EPOLBALDH1A1TACR1HCAR2
SCHEMBL6337042 0.94 KDM4E (0.45) KDM4EPOLBALDH1A1MAPK10KMT2A
SCHEMBL6341590 0.94 KDM4E (0.45) KDM4EPOLBALDH1A1MAPK10KMT2A
SCHEMBL6346010 0.89 PDE5A (0.49) KDM4EPOLBALDH1A1TACR1MAPK10
SCHEMBL6346008 0.89 PDE5A (0.49) KDM4EPOLBALDH1A1TACR1MAPK10
SCHEMBL6347630 0.86 ALDH1A1 (0.44) KDM4EPOLBALDH1A1HCAR2MAPK10
SCHEMBL6347628 0.86 ALDH1A1 (0.44) KDM4EPOLBALDH1A1HCAR2MAPK10
SCHEMBL6348813 0.85 ALDH1A1 (0.43) KDM4EPOLBALDH1A1HCAR2MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890932-B2 Immunoglobulin e antibody suppressors TEIJIN LIMITED (JP) 2005-05-10 US disclosed
EP-1101755-B1 ANTHRANILIC ACID DERIVATIVES TEIJIN LTD (JP) 2004-10-06 EP disclosed
US-20030232811-A1 Immunoglobulin e antibody suppressors TEIJIN LIMITED 2003-12-18 US disclosed
US-6649656-B1 Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents TEIJIN LIMITED (JP) 2003-11-18 US disclosed
EP-1101755-A1 ANTHRANILIC ACID DERIVATIVES TEIJIN LIMITED (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232811-A1 Immunoglobulin e antibody suppressors IGLV6-57, FCGRT, IGSF11 KDM4E 875/4885POLB 3916/4885ALDH1A1 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.